An article published this year in “JOURNAL OF EXPERIMENTAL &
CLINICAL CANCER RESEARCH” using our Annexin V binding assay, by our customers from
Center for tumor-related epilepsy, Area of Supporting Care, Regina Elena
National Cancer Institute, Rome, Italy, in the analysis of In vitro
antineoplastic effects of brivaracetam and lacosamide on human glioma cells.
Congrats and Thanks.
Summary:
Background: Epilepsy is a
frequent symptom in patients with glioma. Although treatment with antiepileptic
drugs is generally effective in controlling seizures, drug-resistant patients
are not uncommon. Multidrug resistance proteins (MRPs) and P-gp are
over-represented in brain tissue of patients with drug-resistant epilepsy,
suggesting their involvement in the clearance of antiepileptic medications. In
addition to their anticonvulsant action, some drugs have been documented for
cytotoxic effects. Aim of this study was to evaluate possible in vitro
cytotoxic effects of two new-generation antiepileptic drugs on a human glioma
cell line U87MG.
Methods: Cytotoxicity of
brivaracetam and lacosamide was tested on U87MG, SW1783 and T98G by MTS assay.
Expression of chemoresistance molecules was evaluated using flow cytometry in
U87MG and human umbilical vein endothelial cells (HUVECs). To investigate the
putative anti-proliferative effect, apoptosis assay, microRNA expression
profile and study of cell cycle were performed.
Results: Brivaracetam and
lacosamide showed a dose-dependent cytotoxic and anti-migratory effects.
Cytotoxicity was not related to apoptosis. The exposure of glioma cells to
brivaracetam and lacosamide resulted in the modulation of several microRNAs;
particularly, the effect of miR-195-5p modulation seemed to affect cell cycle,
while miR-107 seemed to be implicated in the inhibition of cells migration.
Moreover, brivaracetam and lacosamide treatment did not modulate the expression
of chemoresistance-related molecules MRPs1-3-5, GSTπ, P-gp on U87MG and HUVECs.
Conclusion: Based on
antineoplastic effect of brivaracetam and lacosamide on glioma cells, we assume
that patients with glioma could benefit by the treatment with these two
molecules, in addition to standard therapeutic options.
Reference:
Product link:
Annexin V binding assay: http://www.immunostep.com/apoptosis-tools/3731-anxvf-200t.html
No comments:
Post a Comment